The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

The drug has seen strong demand in the US and Europe, and its India launch is part of Lilly’s broader strategy to expand ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...

Global pharmaceutical company Eli Lilly and Company (India) has introduced Mounjaro (tirzepatide) in India, a breakthrough drug for the treatment of Type 2 diabetes and obesity. Approved by the ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said ...

Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.